Join
Live feed
·
PRReleasevia Quantisnow
Silo Pharma Inc. logo

Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15

ByQuantisnow·Wall Street's wire, on your screen.
SILO· Silo Pharma Inc.
Consumer Discretionary

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SILO (Silo Pharma Inc.) and more on Quantisnow.